OmniSpirant Limited has received funding from the European Union’s Horizon 2020 research and innovation programme under SME Instrument grant agreement 855463_ReSpire

The Celtic Advanced Life Science Innovation Network (CALIN) is a 4-year Ireland-Wales INTERREG operation funded by the European Regional Development Fund through the Welsh Government.

Registered Address

Clonmel, Co. Tipperary, Ireland

Contact

©2019 OMNISPIRANT LIMITED

OmniSpirant Limited was founded by Gerry McCauley in 2016. Gerry qualified as a Master of Pharmacy in 2001. Gerry has extensive commercial knowledge, industry contacts and has built an international network of experts in the fields of cell and gene therapy and respiratory drug delivery.
Gerry is the inventor of OmniSpirant’s patent pending inhaled exosome technology. Ongoing Cystic Fibrosis (CF) research is expected to generate game changing in vitro data by Q2 2020. OS002, our discovery stage COPD program, has the game changing potential to reverse established disease damage and restore lung function. OmniSpirant are currently seeking seed investment to fund further CF and COPD preclinical studies and develop scalable GMP manufacturing of the novel exosome therapeutics.  In time, it is hoped that similar breakthrough potential can be unlocked in treating other lung diseases of high unmet patient need - e.g. Lung Adenocarcinoma, Pulmonary Hypertension and IPF.